IDH2 and glioma: Patients with IDH-mutant glioma have better clinical outcomes compared with patients suffering from IDH-wildtype glioma [5,6], suggesting that there are unique physiological characteristics of IDH-mutant gliomas that may make them particularly vulnerable to specific therapies.